Abstract
Tamoxifen, a selective estrogen receptor modulator (SERM), remains a cornerstone adjuvant treatment for hormone receptor positive breast cancer because of its anti-estrogenic effects on breast tissue. However, its partial estrogen-like activity on the endometrium raises concerns about endometrial thickening and related pathologies. Recent data indicate that up to 66% of women receiving tamoxifen show an endometrial thickness of 8 mm on ultrasound. According to several studies, about 50 60% of women on tamoxifen have an endometrium measuring 8 mm on imaging, yet more than half of these cases reveal a benign or atrophic endometrium on biopsy, highlighting that routine invasive investigations may be unnecessary in asymptomatic patients. This mismatch between imaging findings and histology calls into question the value of systematic invasive evaluation in women without symptoms.A review of recent clinical and imaging studies, predictive models incorporating machine learning, and updated clinical guidelines suggests that risk stratification could be improved through nomograms that integrate both clinical and radiologic data
Full text
1,692 characters
· extracted from
oa-html
· click to expand
ENDOMETRIAL THICKENING IN PATIENTS ON TAMOXIFEN: CURRENT INSIGHTS AND MANAGEMENT STRATEGIES
- Abstract
- How to Cite This Article
- Corresponding Author
Tamoxifen, a selective estrogen receptor modulator (SERM), remains a cornerstone adjuvant treatment for hormone receptor positive breast cancer because of its anti-estrogenic effects on breast tissue. However, its partial estrogen-like activity on the endometrium raises concerns about endometrial thickening and related pathologies. Recent data indicate that up to 66% of women receiving tamoxifen show an endometrial thickness of 8 mm on ultrasound. According to several studies, about 50 60% of women on tamoxifen have an endometrium measuring 8 mm on imaging, yet more than half of these cases reveal a benign or atrophic endometrium on biopsy, highlighting that routine invasive investigations may be unnecessary in asymptomatic patients. This mismatch between imaging findings and histology calls into question the value of systematic invasive evaluation in women without symptoms.A review of recent clinical and imaging studies, predictive models incorporating machine learning, and updated clinical guidelines suggests that risk stratification could be improved through nomograms that integrate both clinical and radiologic data
Douha Ziane (2025); ENDOMETRIAL THICKENING IN PATIENTS ON TAMOXIFEN: CURRENT INSIGHTS AND MANAGEMENT STRATEGIES, Int. J. of Adv. Res., 13 (08), 1376-1378, ISSN 2320-5407. DOI URL: https://dx.doi.org/10.21474/IJAR01/21632
Department of Gynecology and Obstetrics, University Hospital Center MohamedVI of Tangier, Facultyof Med icine and Pharmacy of Tangier, AbdelmalekEssaadi University, Morocco.
Morocco
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.